These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 6369734)

  • 61. Extreme insulin resistance: clinical management by external subcutaneous insulin infusion.
    Lalej-Bennis D; Selam JL; Fluteau-Nadler S; M'Bemba J; Reach G; Sorel G; Bardin C; Zirinis P; Chast F; Elgrably F; Slama G
    Diabetes Metab; 1997 Dec; 23(6):533-6. PubMed ID: 9496561
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment.
    Lepore G; Dodesini AR; Nosari I; Trevisan R
    Diabetes Care; 2003 Apr; 26(4):1321-2. PubMed ID: 12663625
    [No Abstract]   [Full Text] [Related]  

  • 63. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial.
    Hoogma RP; Hammond PJ; Gomis R; Kerr D; Bruttomesso D; Bouter KP; Wiefels KJ; de la Calle H; Schweitzer DH; Pfohl M; Torlone E; Krinelke LG; Bolli GB;
    Diabet Med; 2006 Feb; 23(2):141-7. PubMed ID: 16433711
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Continuous glucose monitoring and intensive treatment of type 1 diabetes.
    ; Tamborlane WV; Beck RW; Bode BW; Buckingham B; Chase HP; Clemons R; Fiallo-Scharer R; Fox LA; Gilliam LK; Hirsch IB; Huang ES; Kollman C; Kowalski AJ; Laffel L; Lawrence JM; Lee J; Mauras N; O'Grady M; Ruedy KJ; Tansey M; Tsalikian E; Weinzimer S; Wilson DM; Wolpert H; Wysocki T; Xing D
    N Engl J Med; 2008 Oct; 359(14):1464-76. PubMed ID: 18779236
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol.
    Bally L; Thabit H; Tauschmann M; Allen JM; Hartnell S; Wilinska ME; Exall J; Huegel V; Sibayan J; Borgman S; Cheng P; Blackburn M; Lawton J; Elleri D; Leelarathna L; Acerini CL; Campbell F; Shah VN; Criego A; Evans ML; Dunger DB; Kollman C; Bergenstal RM; Hovorka R
    BMJ Open; 2017 Jul; 7(7):e016738. PubMed ID: 28710224
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparison between continuous subcutaneous insulin infusion and multiple injections of insulin. A one-year prospective study.
    Schiffrin A; Belmonte MM
    Diabetes; 1982 Mar; 31(3):255-64. PubMed ID: 6759242
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Insulin treatment: a non-stop revolution.
    Mirouze J
    Diabetologia; 1983 Sep; 25(3):209-21. PubMed ID: 6357909
    [No Abstract]   [Full Text] [Related]  

  • 68. [Continuous subcutaneous insulin infusion in diabetes mellitus type 1 and 2: lower HbA1c-values and a high level of patient satisfaction].
    de Borst JM; Berghout A
    Ned Tijdschr Geneeskd; 2003 Oct; 147(41):2021-5. PubMed ID: 14587146
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Continuous Glucose Monitoring in Patients With Type 1 Diabetes Taking Insulin Injections.
    Davidson MB
    JAMA; 2017 Jan; 317(4):363-364. PubMed ID: 28118435
    [No Abstract]   [Full Text] [Related]  

  • 70. Assessment of glycemic variability in continuous subcutaneous insulin infusion therapy in type 1 diabetes related to anthropometry and complication status.
    Mehdi SK; Hatfield E; Dornhorst A; Oliver NS
    J Diabetes Sci Technol; 2009 Sep; 3(5):1227-8. PubMed ID: 20144442
    [No Abstract]   [Full Text] [Related]  

  • 71. Reduction of severe hypoglycemic events in type I (insulin dependent) diabetic patients using continuous subcutaneous insulin infusion.
    Eichner HL; Selam JL; Holleman CB; Worcester BR; Turner DS; Charles MA
    Diabetes Res; 1988 Aug; 8(4):189-93. PubMed ID: 3148381
    [TBL] [Abstract][Full Text] [Related]  

  • 72. SHBG (sex hormone binding globulin) levels in insulin dependent diabetic patients according to the route of insulin administration.
    Lassmann-Vague V; Raccah D; Pugeat M; Bautrant D; Belicar P; Vague P
    Horm Metab Res; 1994 Sep; 26(9):436-7. PubMed ID: 7835829
    [No Abstract]   [Full Text] [Related]  

  • 73. Sensor Augmented Pump Therapy Use in Type 1 Diabetes Mellitus.
    Carolan E; Murphy NP
    Ir Med J; 2016 Dec; 109(10):477. PubMed ID: 28644582
    [No Abstract]   [Full Text] [Related]  

  • 74. The suboptimal roadmap to the intensive therapy target.
    Davidson P; Hebblewhite H; Steed RD; Bode B
    Diabetes Technol Ther; 2004 Feb; 6(1):17-9. PubMed ID: 15000765
    [No Abstract]   [Full Text] [Related]  

  • 75. Long-term safety and efficacy of programmable implantable insulin delivery systems.
    Olsen CL; Liu G; Iravani M; Nguyen S; Khourdadjian K; Turner DS; Waxman K; Selam JL; Charles MA
    Int J Artif Organs; 1993 Dec; 16(12):847-54. PubMed ID: 8175202
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Management of "brittle" diabetes with a preprogrammable implanted insulin pump delivering intraperitoneal insulin.
    Wood DF; Goodchild K; Guillou P; Thomas DJ; Johnston DG
    BMJ; 1990 Nov; 301(6761):1143-4. PubMed ID: 2252927
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial.
    Weintrob N; Benzaquen H; Galatzer A; Shalitin S; Lazar L; Fayman G; Lilos P; Dickerman Z; Phillip M
    Pediatrics; 2003 Sep; 112(3 Pt 1):559-64. PubMed ID: 12949284
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Treatment and glycemic control of 1200 diabetic patients enrolled at the National Institute of Disease-Disability Insurance diabetes convention].
    Buysschaert M; Maes M; Hermans MP
    Acta Clin Belg; 1997; 52(4):211-8. PubMed ID: 9412121
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effectiveness of Continuous Subcutaneous Insulin Infusion Pump Therapy During Five Years of Treatment on Metabolic Control in Children and Adolescents with Type 1 Diabetes Mellitus.
    Korkmaz Ö; Demir G; Çetin H; Mecidov İ; Atik Altınok Y; Özen S; Darcan Ş; Gökşen D
    J Clin Res Pediatr Endocrinol; 2018 Jun; 10(2):147-152. PubMed ID: 29537377
    [TBL] [Abstract][Full Text] [Related]  

  • 80. New Design of a Percutaneous Port System for Continuous Intraperitoneal Insulin Infusion.
    Rieger C; Kurz K; Mueller-Hoffmann W; Gehr B; Liebl A
    J Diabetes Sci Technol; 2019 Nov; 13(6):1158-1160. PubMed ID: 31195815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.